-
LOCALLY SOURCED
To find and license promising
development candidates from
domestic biotech/pharma
companies and universities -
REGIONALLY FINANCED
To establish sources of financing
from regional investment
communities -
GLOBALLY DEVELOPED
To develop assets up to human
PoC(Proof of Concept) globally
Pipeline
We have initially focused on small molecular entities (SME) for the treatment of inflammatory and fibrotic diseases and are gradually expanding our interests to the immuno-oncology field with advanced modalities.
News
Bridge Biotherapeutics Presented Preclinical and Phase I Study Results for BBT-401 at the Crohn's & Colitis Congress
Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company presented the preclinical and the Phase I study results for BBT-401, a drug candidate for Ulcerative Colitis (UC) treatment, at the poster session of the Crohn's & Colitis Congress held in Las Vegas, NV from February 7th to 9th. The congress, which is based on a par...
Read More-
LEARN MORE ABOUT US
-
CONTACT INFORMATION
HQ: Suite 903-2, Bldg B, Innovalley, 253 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486 Republic of Korea
US Office: Bridge Biotherapeutics, Inc. in JLABS@TMC, 2450 Holcombe Blvd. Houston, TX 77021, USADirector, Jong-jin Lim (jong-jin.lim@bridgebiorx.com)
Manager, Joengbin Ahn (Joengbin.ahn@bridgebiorx.com)